Intellia Therapeutics, Inc. – NTLA
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA).
On October 27, 2025, Intellia reported that “. . . it has temporarily paused dosing and screening in the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for nexiguran ziclumeran (‘nex-z’).”
Intellia stated that “[t]his action follows a report on October 24, 2025 of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in the MAGNITUDE trial on September 30, 2025, meeting the trial’s protocol-defined pausing criteria.”
On this news, Intellia’s stock price dropped more than 45% in pre-market trading on October 27, 2025.
On October 29, 2025, Intellia reported that the “. . . verbally informed the Company that the FDA has placed a clinical hold on the Investigational New Drug applications for the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for nexiguran ziclumeran (“nex-z”). FDA indicated that it would provide a formal Clinical Hold Letter within 30 calendar days.”
Intellia also reported that the “. . . clinical hold follows the previously disclosed report of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in the MAGNITUDE trial. As previously announced on October 27, 2025, the Company had temporarily paused dosing and screening in the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for nex-z based on the MAGNITUDE trial’s protocol-defined pausing criteria.”
On this news after the market closed on October 29, 2025, Intellia’s stock price was down more than 16%.
Intellia Investors May Have Legal Claims
Investors of Intellia stock with financial losses are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to learn more about the investigation and receive a free, no-obligation evaluation of potential legal claims.
About Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.
Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.
Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.
SEND US A MESSAGE
Contact Us
ADDRESS
Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103